Citations

Clear

1526 citation(s) found for "Sun, Bo".

Self-reported quality-of-life (QoL) impairment and productivity loss in patients with polycythemia vera (PV) enrolled in the REVEAL study.
Boccia, Ralph V., Moliterno, Alison R. , Stein, Brady L. , Naim, Ahmad, Cordaro, Joseph A., Parasuraman, Shreekant , Grunwald, Michael R. , Oh, Stephen T. , Peng, Wei Jun , Sun, Haowei , Mesa, Ruben A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e18561-e18561

10.1200/jco.2016.34.15_suppl.e18561 Get It

Disease, clinical, and treatment characteristics of patients (pts) with polycythemia vera (PV) enrolled in the REVEAL study.
Stein, Brady L. , Moliterno, Alison R. , Boccia, Ralph V., Naim, Ahmad, Cordaro, Joseph A., Parasuraman, Shreekant , Grunwald, Michael R. , Oh, Stephen T. , Peng, Wei Jun , Sun, Haowei , Mesa, Ruben A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e18557-e18557

10.1200/jco.2016.34.15_suppl.e18557 Get It

PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).
Tobinai, Kensei , Lin, Tongyu , Vanazzi, Anna , Hino, Masayuki , Shi, Yuankai , Mayer, Jiřı́ , Bermúdez, Carlos , Zhu, Jun , Bouabdallah, Kamal , Kattan, Joseph , Wu, Cassandra, Fan, Jenna, Louveau, Anne-Laure, Voi, Maurizio, Cavalli, Franco , Witzig, Thomas E. , Rigacci, Luigi , Ikeda, Takashi , Costa, Luciano J. , Belada, David

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7506-7506

10.1200/jco.2016.34.15_suppl.7506 Get It

Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.
Catalano, John, Deininger, Michael W. , Miller, Carole B., Silver, Richard T. , Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O. , Lyons, Roger M. , Paquette, Ronald , Raza, Azra , Kornacki, Deanna , Sun, Kang , investigators, COMFORT-I, Gupta, Vikas , Verstovšek, Srđan , Mesa, Ruben A. , Gotlib, Jason , DiPersio, John F. , Talpaz, Moshe , Hexner, Elizabeth O. , Kantarjian, Hagop M. , investigators, COMFORT-I

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7012-7012

10.1200/jco.2016.34.15_suppl.7012 Get It

Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).
Denlinger, Crystal S. , Sym, Sun Jin , Bendell, Johanna C. , Kudla, Art, McDonagh, Charlotte F., Czibere, Akos, Chibaudel, Benoist , Yoon, Harry H. , Hecht, J. Randolph, Bang, Yung‐Jue, Maqueda, María , Watkins, David J. , Park, Se Hoon , Arkenau, Hendrik‐Tobias , Bekaii‐Saab, Tanios , Press, Michael F. , Cunningham, David , Bang, Yung‐Jue , Chibaudel, Benoist

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4043-4043

10.1200/jco.2016.34.15_suppl.4043 Get It

IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).
Powles, Thomas, Pal, Sumanta K. , Hainsworth, John D. , Qiu, Jiaheng, Huseni, Mahrukh , Schiff, Christina, Escudier, Bernard , Atkins, Michael B. , McDermott, David F. , Powles, Thomas , Motzer, Robert J. , Rini, Brian I. , Fong, Lawrence , Joseph, Richard W. , Stadler, Walter M. , Hutson, Thomas E. , Ravaud, Alain , Bracarda, Sergio , Suárez, Cristina , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 4505-4505

10.1200/jco.2017.35.15_suppl.4505 Get It

4505 Background: While inhibiting VEGF improves outcomes in mRCC pts, most develop resistance, often within a year. Here, we report results from a Ph II study of atezo (anti–PD-L1) and bev (anti-VEGF) vs and following atezo or sun (TKI) in mRCC pts. Methods: Pts with untreated mRCC were enrolled in the hypothesis generating IMmotion150 study (NCT01984242) and randomized to atezo 1200 mg IV q3w + bev 15 mg/kg IV q3w, atezo alone or sun 50 mg PO QD 4 wk on/2 wk off. After progression on atezo or sun, crossover to atezo + bev was allowed. PD-L1 status was scored on tumor-infiltrating immune cells (IC, SP142 IHC assay). The primary analysis was modified prior to final analysis to reflect the coprimary endpoints of IRF-assessed PFS (RECIST v1.1) in ITT pts and pts with PD-L1 expression on ≥ 1% of IC (PD-L1+). Results: 54% of pts were PD-L1+. In PD-L1+ pts 1L treatment resulted in a PFS hazard ratio (HR) of 0.64 for atezo + bev vs sun (table). After 1L treatment, 78% of sun and 60% of atezo pts who progressed subsequently received atezo + bev and achieved ORRs of 28% and 24%, respectively (table). Safety was comparable to the known individual profiles of atezo and bev. Additional clinical, safety and biomarker data will be presented. Conclusions: Atezo + bev resulted in encouraging antitumor activity in 1L pts with PD-L1+ mRCC. Preliminary activity in the 2L setting was demonstrated in pts who crossed over to atezo + bev, regardless of prior therapy. 1L atezo + bev vs sun is being evaluated in the ongoing Ph III study IMmotion151 (NCT02420821). Clinical trial information: NCT01984242. [Table: see text]
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.
Fuchs, Charles S. , Doi, Toshihiko , Jang, Raymond Woo-Jun, Muro, Kei , Sun, Weijing , Jalal, Shadia I. , Garrido, Marcelo , Golan, Talia , Mandalà, Mario , Catenacci, Daniel V.T. , Wang, Jiangdian, Koshiji, Minori, Dalal, Rita P., Yoon, Harry H. , Satoh, Taroh , Machado, Manuela , Shah, Manish A , Metges, Jean‐Philippe , Wainberg, Zev A. , Bang, Yung‐Jue

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 4003-4003

10.1200/jco.2017.35.15_suppl.4003 Get It

4003 Background: Pembro has shown promising antitumor activity and manageable safety in a phase 1 study of pts with previously treated advanced gastric cancer. We conducted a global, multicohort, phase 2 study of pembro in pts with advanced gastric or gastroesophageal junction (G/GEJ) cancer (KEYNOTE-059;NCT02335411). Methods: Cohort 1 enrolled 259 pts, aged ≥18 y with measurable recurrent or metastatic G/GEJ adenocarcinoma who had progressed on ≥2 prior chemotherapy regimens and had ECOG PS 0-1. Pts received pembro 200 mg Q3W up to 2 y or up to disease progression, investigator/pt decision to withdrawal, or unacceptable toxicity. PD-L1+pts had expression in ≥1% tumor or stromal cells using IHC (22C3 antibody). Primary end points: ORR (RECIST 1.1, by central review), safety, and tolerability. Results: Of 259 pts in cohort 1, 76.4% were men; median age was 62.0 y. 51.7% and 48.3% received pembro as 3rd-line (3L) and 4L+ therapy, respectively. 57.1% had PD-L1+ tumors. At data cutoff (Oct 19, 2016), median duration of follow-up was 5.4 mo (range, 0.5 to 18.7). Overall ORR (CR + PR) was 11.2% (95% CI, 7.6-15.7); 1.9% of pts (95% CI, 0.6-4.4) had CR, 9.3% had PR (95% CI, 6.0-13.5), 17% (95% CI, 12.6-22.1) had SD, and 55.6% (95% CI, 49.3-61.7) had PD. Median DOR was 8.1 mo (range, 1.4+ to 15.1+). ORR was 14.9% (95% CI, 9.4-22.1) in 3L pts and 7.2% (95% CI, 3.3-13.2) in 4L+. In PD-L1+ pts, ORR was 15.5% (95% CI, 10.1-22.4) with 2.0% (95% CI, 0.4-5.8) CR and 13.5% (95% CI, 8.5-20.1) PR; in PD-L1– pts, ORR was 5.5% (95% CI, 2.0-11.6), with 1.8% (95% CI, 0.2-6.5) CR and 3.7% (95% CI, 1.0-9.1) PR. In 3L pts with PD-L1+ tumors, ORR was 21.3% (95% CI, 12.7-32.3), with 4.0% (95% CI, 0.8-11.2) CR; in 3L pts with PD-L1– tumors, ORR was 6.9% (95% CI, 1.9-16.7), with 3.4% (95% CI, 0.4-11.9) CR. Grade 3-5 treatment-related AEs (TRAEs) occurred in 43 pts (16.6%). TRAEs led to discontinuation in 2 pts (abnormal LFT, bile duct stenosis) and were fatal in 2 pts (acute kidney injury, pleural effusion). Conclusions: Pembro showed encouraging efficacy and manageable safety after ≥2 prior lines of therapy in pts with advanced G/GEJ cancer in this large phase 2 trial. Survival and additional biomarker data, including MSI status, will be presented. Clinical trial information: NCT02335411.
CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).
Grothey, Axel, Xu, Rui‐Hua , Borodyansky, Laura, Li, Chiang, Shah, Manish A , Yoshino, Takayuki , Cutsem, Eric Van , Taı̈eb, Julien , Tebbutt, Niall C. , Falcone, Alfredo , Cervantes, Andrés

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: TPS3619-TPS3619

10.1200/jco.2017.35.15_suppl.tps3619 Get It

TPS3619 Background: Cancer stem cells are considered to be fundamentally important for resistance to therapy, recurrence and metastasis. Napabucasin is a first-in-class cancer stemness inhibitor in development identified by its ability to inhibit STAT3-driven gene transcription and spherogenesis of cancer stem cells (Li et al, PNAS 112(6):1839, 2015). Preclinically, napabucasin sensitizes cancer cells to chemotherapeutics, including 5-FU and irinotecan. Encouraging anticancer activity in advanced CRC was observed in a phase Ib/II (Bendell et al, GI ASCO 2017) study of 63 pts with disease control rate (DCR) of 93% (28/30) and overall response rate (ORR) of 33% (10/30) in FOLFIRI-naïve pts who have had an on-study RECIST evaluation. On the basis of these data, a phase III trial is being conducted in North America, Europe, Australia, and Asia. Methods: This study (ClinicalTrials.gov NCT02753127) will assess the efficacy of napabucasin+FOLFIRI vs FOLFIRI in pts with mCRC (n = 1250). Addition of bevacizumab (bev) is permissible per investigator choice. Pts must have failed 1 prior line of therapy with oxaliplatin and a fluoropyrimidine +/- bev for metastatic disease. Pts are randomized 1:1 to receive napabucasin 240 mg PO BID plus FOLFIRI bi-weekly, or FOLFIRI bi-weekly (bev may be added to FOLFIRI by investigator choice) and stratified by geography, time to progression on 1st-line therapy, RAS mutation status, bev as part of study treatment and primary tumor location. Treatment will continue until disease progression, or another discontinuation criterion. Primary endpoint is overall survival (OS) in the general study population (ITT) (HR 0.80 for OS improvement from 12.54 to 15.68 months); secondary endpoints include OS in the biomarker positive (biomarker+) population, progression free survival (PFS) in the ITT population, PFS in biomarker+ population, ORR and DCR in the ITT and in biomarker+ populations, safety and quality of life. Also, blood and tumor archival tissue will be assessed for PK and biomarker analyses. Global enrollment is underway. Clinical trial information: NCT02753127.
Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance).
Hua, Xinwei , Banbury, Barbara L. , Phipps, Amanda I. , Kocarnik, Jonathan, Harrison, Tabitha A. , Thibodeau, Stephen N. , Chan, Emily , Goldberg, Richard M. , Kahlenberg, Morton S., Nair, Suresh , Shields, Anthony F. , Jahagirdar, Balkrishna, Peters, Ulrike , Harrison, Tabitha A , Newcomb, Polly A. , Sun, Wei , Shi, Qian , Sinicrope, Frank A. , Gill, Sharlene , Alberts, Steven R. , Chan, Andrew T.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3604-3604

10.1200/jco.2017.35.15_suppl.3604 Get It

3604 Background: Limited research has investigated the role of variation in the host genome as a determinant of colon carcinoma (CC) outcomes, including toxicity due to therapeutic agents. We examined the relationship between germline genetic factors and treatment-associated serious adverse events (SAEs) in a population of CC patients in which treatment was standardized and follow-up for outcomes was uniformly conducted. Methods: Using existing biospecimens from CC patients with resected stage III disease in a phase III randomized trial of FOLFOX adjuvant chemotherapy with and without cetuximab (NCCTG N0147), genome-wide genotyping arrays were conducted for 2200 patients for a total of ~20 million single nucleotide polymorphisms (SNPs). Using logistic regression models we assessed SNP-specific associations with SAEs, utilizing a discovery-based approach to search the genome in an unbiased manner. Detailed information on SAEs was collected using the Common Toxicity Criteria for Adverse Events (CTCAE, v3.0). Analyses evaluating associations with specific classes of common grade ≥3 SAEs were performed, including gastrointestinal toxicities, neutropenia, and paresthesias. A threshold of P < 5x10-8was used to denote genome-wide significance. Results: Among patients who received FOLFOX, several SNPs on chr 15 near the ANP32A gene and on chr 2 near the CD207 gene were statistically significantly associated with grade ≥3 neuropathy. The strongest SNP-specific associations in these regions were in the range of odds ratio (OR) = 1.3, P = 2.8×10−10 and OR = 1.5, P = 2.7×10−10, respectively. Conclusions: Findings from this genome-wide analysis demonstrate the potential importance of germline genetic variation in influencing CC patients’ experience of specific toxicities to FOLFOX regimens. These results highlight two genomic regions of potential interest for understanding the biological mechanism for such toxicities, although further evaluation and replication is needed. Support: U10CA180821, U10CA180882, U10CA180820, U10CA180863, U10CA180888, CCSRI 021039, R01CA176272, Eli Lilly & Co, Pfizer, Sanofi. Clinical trial information: NCT00079274 .
A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
Vaishampayan, Ulka N. , Matrana, Marc , Zurita, Amado J. , Keam, Bhumsuk , Sundararajan, Srinath , Mowat, Rex B., Dudek, Arkadiusz Z. , Gan, Lu , Vaishampayan, Ulka , McDermott, David F. , Rha, Sun Young , Ho, Thai H. , Lee, Jae‐Lyun , Joseph, Richard W. , Ali, Sarah, Stadler, Walter M. , Haas, Naomi B , Park, Se Hoon , Picus, Joel , Zakharia, Yousef , Atkins, Michael B. , Dudek, Arkadiusz Z

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4510-4510

10.1200/jco.2018.36.15_suppl.4510 Get It